Companies
Meissner
The highly fragmented US cell therapy market requires hyper-customized, small-volume closed systems (e.g., Meissner) to safely handle autologous patient samples.
- Country
- United States
Commercial
One-Touch
Coverage
| CN | EU | US | |
|---|---|---|---|
| consumables | ✓ | ✓ | ✓ |
Regulatorsfdaema
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $13.4 million government contract from BARDA (April 30, 2021) | biobase.whitefordresearch.com |
| Funding | $3.56 million PPP loan (April 28, 2020) | biobase.whitefordresearch.com |
| Capacity | Plans for a new Georgia campus to double manufacturing capacity in the U.S. | endpoints.news · meissner.com |
| Certification | ISO 11137 methodology for sterility validation | meissner.com |
| Certification | Certified animal component free (ACF) products | meissner.com |
| Production site | Camarillo, California (headquarters and manufacturing) | meissner.com |
| Production site | Castlebar, Ireland (European manufacturing) | endpoints.news · meissner.com |
| Production site | Winterville/Athens, Georgia (planned manufacturing site) | endpoints.news · meissner.com |
Independent sources: biobase.whitefordresearch.com · endpoints.news
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Single-use assemblies | consumables | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.